Citryll
Oss
About Citryll
Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $110.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2024)
- Website: citryll.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Medical, Medical Device, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/citryll-67310 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.